MaxCyte, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.3M | $9.7M | $7.3M | $6.8M | $8.5M | $10.4M | $8.7M | $8.2M |
| Cost of Revenue | $1.7M | $1.6M | $1.6M | $1.6M | $1.5M | $1.5M | $2.3M | $1.9M |
| Gross Profit | $5.6M | $8.1M | $5.7M | $5.2M | $7.0M | $8.9M | $6.4M | $6.2M |
| Gross Margin | 77.0% | 83.7% | 77.9% | 76.6% | 82.1% | 85.6% | 73.8% | 76.4% |
| Operating Expenses | ||||||||
| Research & Development | $4.3M | $3.9M | $3.3M | $5.3M | $6.3M | $5.9M | $4.6M | $5.3M |
| SG&A Expense | $7.3M | $6.0M | $5.5M | $6.0M | $8.1M | $8.5M | $7.2M | $7.7M |
| Operating Income | $-10.2M | $-6.2M | $-11.2M | $-14.1M | $-14.2M | $-12.3M | $-12.9M | $-14.1M |
| Operating Margin | -140.7% | -64.1% | -153.8% | -207.2% | -167.2% | -118.3% | -148.4% | -172.1% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-8.9M | $-4.8M | $-9.6M | $-12.4M | $-12.4M | $-10.3M | $-10.6M | $-11.6M |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-8.9M | $-4.8M | $-9.6M | $-12.4M | $-12.4M | $-10.3M | $-10.6M | $-11.6M |
| Net Margin | -122.0% | -49.2% | -131.5% | -181.8% | -145.3% | -98.8% | -121.9% | -141.6% |
| EPS (Basic) | $-0.08 | $-0.04 | $-0.08 | $-0.12 | $-0.12 | $-0.10 | $-0.10 | $-0.11 |
| EPS (Diluted) | $-0.08 | $-0.04 | $-0.08 | $-0.12 | $-0.12 | $-0.10 | — | $-0.11 |
| Shares Outstanding (Basic) | 106.8M | 106.9M | 106.4M | 106.6M | 106.4M | 106.0M | 104.8M | 105.1M |
| Shares Outstanding (Diluted) | 106.8M | 106.9M | 106.4M | 106.6M | 106.4M | 106.0M | 104.8M | 105.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |